Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials
Journal
Ophthalmology
Date Issued
2024
Author(s)
Wong, Tien Y
Haskova, Zdenka
Asik, Kemal
Baumal, Caroline R
Csaky, Karl G
Eter, Nicole
Ives, Jane A
Jaffe, Glenn J
Korobelnik, Jean-François
Lin, Hugh
Murata, Toshinori
Ruamviboonsuk, Paisan
Schlottmann, Patricio G
Seres, András I
Silverman, David
Sun, Xiaodong
Tang, Yannan
Wells, John A
Yoon, Young Hee
Wykoff, Charles C
Abstract
To evaluate the 2-year efficacy, durability, and safety of dual angiopoietin-2 and vascular endothelial growth factor (VEGF) A pathway inhibition with intravitreal faricimab according to a personalized treat-and-extend (T&E)-based regimen with up to every-16-week dosing in the YOSEMITE and RHINE (ClinicalTrials.gov identifiers, NCT03622580 and NCT03622593, respectively) phase 3 trials of diabetic macular edema (DME).
Subjects
Angiopoietin-2; Diabetic macular edema; Faricimab; Vascular endothelial growth factor A; Vascular stability
Type
journal article